Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

A mobile prostate cancer screening program proved feasible for men in underserved neighborhoods and led to a high rate of ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d ...

(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Poster Session A: Prostate Cancer. Dr. Moein Moradpour ...

The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...